FDA Approves Tapentadol for Relief of Moderate to Severe Acute Pain
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Tapentadol for Relief of Moderate to Severe Acute Pain

NEW YORK -- November 21, 2008 -- The US Food and Drug Administration (FDA) has approved tapentadol immediate-release tablets for the relief of moderate to severe acute pain in adults aged 18 years or older.

The approval was based on data from multiple phase 3 trials involving more than 2,100 patients. The studies showed that tapentadol provided significant relief of moderate to severe acute pain when compared with placebo. The medicine was also generally well tolerated.

The studies were conducted in different patient groups, including those who had a bunionectomy, those with pain from end-stage joint disease, and in patients with low back pain or pain from osteoarthritis of the hip or knee.

SOURCE: Johnson & Johnson

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities